Accretion Pharmaceuticals Ltd vs Mono Pharmacare Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 10, 2026

Key Highlights

The Latest Trading Price of Accretion Pharmaceuticals Ltd is ₹ 117.75 as of 08 May 15:30 . The P/E Ratio of Accretion Pharmaceuticals Ltd is 0 as of March 2023 .The P/E Ratio of Mono Pharmacare Ltd is 0 as of March 2023 . The Market Cap of Accretion Pharmaceuticals Ltd is ₹ 0 crore as of March 2023 .The Market Cap of Mono Pharmacare Ltd is ₹ 0 crore as of March 2023 . The Dividend Payout of Accretion Pharmaceuticals Ltd is 0 % as of March 2023 .The Dividend Payout of Mono Pharmacare Ltd is 0 % as of March 2023.

About Accretion Pharmaceuticals Ltd

Accretion Pharmaceuticals was incorporated in year 2012, the Promoters Mr. Harshad Nanubhai Rathod, Mr. Vivek Ashok Kumar Patel, Mr. Mayur Popatlal Sojitra and Mr. Hardik Mukundbhai Prajapati, came together to establish a pharmaceutical manufacturing unit, to provide health care products.
Thus, the foundation of 'Accretion Pharmaceuticals' was laid down, which was started as a Partnership Firm in the name of 'M/s Accretion Pharmaceuticals', pursuant to a deed of partnership dated December 18, 2012. The manufacturing facility which is currently located at Ahmedabad, in Sanand District of Gujarat, commenced its manufacturing operations in 2014.
Thereafter, the Partnership Firm was converted into a Limited Company in the name of 'Accretion Pharmaceuticals Limited' and a certificate of incorporation dated November 29, 2023 was issued by the Registrar of Companies, Central Registration Centre, for and on behalf of the jurisdictional Registrar of Companies.

About Mono Pharmacare Ltd

Mono Pharmacare Limited was originally formed as a Partnership Firm in the name and style of 'M/s.
Mono Chemist' through Partnership Deed dated May 06, 1994.
The Partnership Firm was then converted into Public Limited company in the name of Mono Pharmacare Limited vide Certificate of Incorporation dated October 17, 2022, was issued by the Registrar of Companies, Ahmedabad.
The Company is engaged in the business of marketing and distribution of pharmaceutical products. The product portfolio comprises of a wide range of drugs like Antibiotics, Antifungal, Anti CoughCold & Anti-allergic, Antacid and Antiemetics, Analgesics and Antipyretics, Nutraceuticals, Skincare, Antiseptic, Cardiac and Diabetic & Cosmetics etc. getting products manufactured through contract manufacturing. Supal Distributors LLP, a Partnership Firm, was incorporated on November 24, 2016, with the Promoters of Company, Panilam Lakhatariya and Supal Lakhatariya, being the Original Partners.

FAQs for the comparison of Accretion Pharmaceuticals Ltd and Mono Pharmacare Ltd

Which company has a larger market capitalization, Accretion Pharmaceuticals Ltd or Mono Pharmacare Ltd?

Market cap of Accretion Pharmaceuticals Ltd is 130 Cr while Market cap of Mono Pharmacare Ltd is 23 Cr

What are the key factors driving the stock performance of Accretion Pharmaceuticals Ltd and Mono Pharmacare Ltd?

The stock performance of Accretion Pharmaceuticals Ltd and Mono Pharmacare Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Accretion Pharmaceuticals Ltd and Mono Pharmacare Ltd?

As of May 10, 2026, the Accretion Pharmaceuticals Ltd stock price is INR ₹117.75. On the other hand, Mono Pharmacare Ltd stock price is INR ₹13.1.

How do dividend payouts of Accretion Pharmaceuticals Ltd and Mono Pharmacare Ltd compare?

To compare the dividend payouts of Accretion Pharmaceuticals Ltd and Mono Pharmacare Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.